Year-to-date revenue is approximately 30.1 million euros (35.9 million US dollars), a year-on-year increase of 14.4%
Revenue in the third quarter was 9.4 million euros ($11.1 million), the same as the third quarter of 2020, reflecting the lingering impact of COVID-19 on capital equipment sales
Year-to-date, the number of HIFU treatments in the United States has increased by 58% over the same period in 2020; urologists adopt Focal One’s powerful leading indicators
Strong cash position of 45.4 million euros (52.6 million US dollars)
The company will host a conference call tomorrow (Thursday, November 18th, US Eastern Time) at 8:30 am
Lyon, France, November 17, 2021-EDAP TMS SA (NASDAQ: EDAP) (the "Company"), a global leader in robotic energy therapy, today announced unaudited financial results for the third quarter of 2021 It also provides the latest information on strategic and operational development.
Marc Oczachowski, Chairman and CEO of EDAP, said: “We are pleased with the continued strong growth in the number of HIFU treatments in the United States, which has increased by 58% year-to-date compared to the same period in 2020. This is a very positive sign because it reflects Urologists are increasingly adopting topical treatments. Regarding our third quarter revenue, the COVID-19 pandemic continues to put pressure on hospital capital expenditures, which was further affected by the placement of several machines, which were placed due to logistics Challenges and postponed pandemics in many parts of the world at the beginning of the fourth quarter. Our leading indicators are strong and funds are sufficient. I believe we are ready to exit this year with a new momentum."
Total revenue for the nine months ended September 30, 2021 was 30.1 million euros (35.9 million U.S. dollars), an increase of 14.4% from the total revenue of 26.3 million (29.8 million U.S. dollars) for the same period in 2020.
Total revenue from HIFU business for the nine months ended September 30, 2021 was 5.7 million euros (6.8 million US dollars), a decrease of 18.9% from the 7.1 million euros (8 million US dollars) for the nine months ended September 30, 2020 .
The total revenue of the LITHO business for the nine months ended September 30, 2021 was 7.7 million euros (9.1 million U.S. dollars), a decrease of 7.4% from the 8.3 million euros (9.4 million U.S. dollars) for the nine months ended September 30, 2020 .
For the nine months ended September 30, 2021, the total revenue of the distribution business was 16.7 million euros (19.9 million U.S. dollars), an increase of 52.4 from the 11 million euros (12.4 million U.S. dollars) for the nine months ended September 30, 2020 %.
Gross profit for the nine months ended September 30, 2021 was 12.2 million euros (14.6 million U.S. dollars), compared with 11.4 million euros (12.8 million U.S. dollars) in the same period last year. The gross profit margin for net sales for the nine months ended September 30, 2021 was 40.6%, compared to 43.2% for the 2020 comparable period. Especially in the HIFU business.
Operating expenses for the nine months ended September 30, 2021 were 14.3 million euros ($17 million), compared to 12.8 million euros ($14.5 million) for the same period in 2020.
The operating loss for the nine months ended September 30, 2021 was 2.1 million euros (2.5 million U.S. dollars), while the operating loss for the nine months ended September 30, 2020 was 1.5 million euros (1.6 million U.S. dollars).
The net loss for the nine months ended September 30, 2021 was EUR 700,000 (USD 0.8 million) or 0.02 EUR (EUR 0.02) per diluted share, while the net loss was EUR 2.5 million (USD 2.8 million) or 0.09 Euro (0.09 Euro)) Diluted earnings per share in the same period last year.
Total revenue for the third quarter of 2021 was 9.4 million euros (11.1 million U.S. dollars), roughly the same as the total revenue of 9.4 million euros (11.2 million U.S. dollars) for the same period in 2020.
The total revenue of the HIFU business in the third quarter of 2021 was 1.9 million euros (2.3 million U.S. dollars), a decrease of 25.6% compared with the 2.6 million euros (3 million U.S. dollars) in the third quarter of 2020.
The total revenue of the LITHO business in the third quarter of 2021 was 2.5 million euros (2.9 million US dollars), an increase of 3.0% from the 2.4 million euros (2.9 million US dollars) in the third quarter of 2020.
The total revenue of the distribution business in the third quarter of 2021 was 5 million euros (5.9 million U.S. dollars), an increase of 13.4% compared to the 4.4 million euros (5.2 million U.S. dollars) in the third quarter of 2020.
Gross profit for the third quarter of 2021 was 3.6 million euros (4.3 million U.S. dollars), compared with 4 million euros (4.7 million U.S. dollars) in the same period last year. The gross profit margin of net sales in the third quarter of 2021 was 38.4%, compared with 42.0% in the same period last year. The year-on-year decrease in gross profit was due to the reduced sales effect of fixed costs, especially for the HIFU business.
Operating expenses for the third quarter of 2021 were 5.5 million euros (6.5 million U.S. dollars), compared to 4.3 million euros (5 million U.S. dollars) for the same period in 2020.
The operating loss in the third quarter of 2021 was 1.9 million euros ($2.2 million), while the operating loss in the third quarter of 2020 was 300,000 euros ($300,000).
The net loss for the third quarter of 2021 was EUR 1 million (USD 1.2 million) or diluted earnings per share (EUR 0.03), compared to a net loss of EUR 1 million (USD 1.2 million) or diluted earnings per share (0.03 EUR). Euro) the share of the same period last year.
As of September 30, 2021, the company held 45.4 million euros (52.6 million U.S. dollars) in cash and cash equivalents, compared with 24.7 million euros (30.2 million U.S. dollars) as of December 31, 2020.
The management will conduct an accompanying conference call and webcast to review the results. The conference call will be held tomorrow (November 18, 2021) at 8:30 AM Eastern Time. For conference call dial-in information and webcast registration information, please refer to the following information.
Conference call and webcast Thursday, November 18, 2021 at 8:30 am Eastern Time Domestic: 877-451-6152 International: 201-389-0879 Password: 13724088 Webcast: https://viavid.webcasts.com/starthere. jsp?ei =1503943&tp_key=7d846a9985
After the conference call, a replay will be provided under "Investor Information" on the company's website www.edap-tms.com.
As a recognized leader in the global therapeutic ultrasound market, EDAP TMS uses ultrasound technology to develop, manufacture, promote and distribute minimally invasive medical devices for various pathologies worldwide. By combining the latest technologies in imaging and treatment methods in its complete line of robotic HIFU equipment, EDAP TMS has launched Focal One® in Europe and the United States to meet all requirements for ideal prostate tissue ablation. With the addition of ExactVu™ micro ultrasound equipment, EDAP TMS is now the only company that provides a complete solution from diagnosis to local treatment of prostate cancer. EDAP TMS also manufactures and distributes other medical equipment, including Sonolith® i-move lithotripters and lasers, used to treat urinary stones using extracorporeal shock wave lithotripsy (ESWL). For more information about the company, please visit http://www.edap-tms.com and us.hifu-prostate.com.
In addition to historical information, this press release also contains forward-looking statements. Such statements are based on management’s current expectations and are subject to many risks and uncertainties, including matters that we do not yet understand or that we currently consider to be unimportant, and there is no guarantee that expected events will occur or that the set goals will actually come out. Will come true. Important factors that may cause actual results to differ materially from the expected results in the forward-looking statements include, among them, the clinical condition and market acceptance of our HIFU devices and the continued market potential of our gravel and distribution divisions, as well as the COVID-19 pandemic The duration and severity, including its impact on our business’ demand for our equipment and services. Factors that may cause such discrepancies may also include but are not limited to the factors described in the company’s filings with the U.S. Securities and Exchange Commission, especially the "Warning Statement of Forward-Looking Information" and "Risk Factors" in the company's annual report 20- F table.
Company Contact Blandine Confort Investor Relations/Legal Affairs EDAP TMS SA 33 4 72 15 31 50 bconfort@edap-tms.com
Investor Contact Information John Fraunces LifeSci Advisors, LLC 917-355-2395 jfraunces@lifesciadvisors.com
EDAP TMS SA's unaudited condensed consolidated operating statement (amounts are in thousands of euros and US dollars, excluding per share data)
Net sales of RPP and leases
Sales of spare parts, supplies and services
S, G & A fees
Currency exchange gains (losses), net
Pre-tax income (loss) and minority shareholders’ equity
Average number of shares used to calculate earnings per share
The average number of shares used to calculate positive net income earnings per share
Note: For the convenience of readers, the average three-month buying price at noon in 2021 is 1 Euro = 1.1747 USD, and the average three-month buying price at noon in 2020 is 1 Euro = 1.1832 USD converted into USD
EDAP TMS SA's unaudited condensed consolidated operating statement (amounts are in thousands of euros and US dollars, excluding per share data)
Net sales of RPP and leases
Sales of spare parts, supplies and services
S, G & A fees
Currency exchange gains (losses), net
Pre-tax income (loss) and minority shareholders’ equity
Average number of shares used to calculate earnings per share
The average number of shares used to calculate positive net income earnings per share
Note: For the convenience of readers, the 9-month average buying price at noon in 2021 1 Euro = 1.1920 USD and the 9-month average buying price at noon in 2020 1 Euro = 1.1319 USD are converted into USD
Highlights of EDAP TMS SA's unaudited consolidated balance sheet (amounts in thousands of euros and US dollars)
Cash, cash equivalents and short-term treasury investments
Real estate, plant and equipment, net
Accounts payable and other accrued liabilities
Obligations under non-current operations and financial leases
Total liabilities and shareholders' equity
Note: For the convenience of readers, the buying price of 1 Euro = 1.1577 USD at noon on September 30, 2021 and the buying price of 1 Euro = 1.2229 USD at noon on December 30, 2020 are converted into USD.
EDAP TMS SA's unaudited consolidated cash flow statement (amount in thousands of euros)
Adjust net income (loss) and net cash (used in) operating activities (1)
Increase/decrease in operating assets and liabilities
Net cash generated by (used in) operating activities
Increase in capitalized assets generated by the company and other capital expenditures
Net cash generated by (used in) investment activities
Net cash generated by (used in) financing activities
The net impact of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
(1) Including 1.154 million euros at the end of September 2021 and 160,000 euros at the end of December 2020 for share compensation expenses.
Note: For the convenience of readers, the average buying price of 1 Euro at noon in 2021 = 1.1920 USD and the 12-month average buying price of 1 Euro at noon = 1.1474 USD are converted into USD for the convenience of readers.
EDAP TMS SA's unaudited branch operating concise statement for the nine months ended September 30, 2021 (amount in thousands of euros)
RPP and lease sales
Sales of spare parts and services
Gross profit (% of total revenue)
SG&A total plus depreciation
2021-11-17 - EDAP approved in the third quarter of 2021
Hangzhou, China, November 18, 2021 - Alibaba Group Holdings Limited today announced its financial results for the quarter ended September 30, 2021.
The "big short" guy is bearish. But not in these three plays.
Teladoc Health (NYSE: TDOC), a telemedicine specialist, took a hit on the stock Thursday. Teladoc forecasts revenue of $2.6 billion in fiscal year 2022, which is higher than analysts’ forecasts of slightly more than $2 billion in revenue for this fiscal year. This forecast is slightly higher than analysts’ average forecast of $2.58 billion in revenue for the 2022 fiscal year.
On the contrary, the problem stems from fuboTV's profit margin-or lack of profit margin. It is losing money rapidly, and is constantly raising funds to dilute shareholders' equity. Let us take a closer look at two reasons why the market is concerned about fuboTV.
So far, it has been a difficult week for Canadian cannabis stocks. According to data from Standard & Poor's Global Market Intelligence, as of Thursday's close, Canopy Growth (NASDAQ: CGC) shares have fallen 19.1% in a week. Cronos Group (NASDAQ: CRON) shares fell 22%.
Just as Apple released its report on electric vehicles, the Dow Jones Index fell. Nvidia soared. The Trump SPAC fell due to the request for an investigation by the US Securities and Exchange Commission.
In this article, we will discuss 10 dividend stocks in Warren Buffett's latest portfolio. If you want to skip our detailed analysis of these stocks, please go directly to the 5 dividend stocks in Warren Buffett's latest portfolio. Warren Buffett (Warren Buffett) was born in Omaha, Berkshire Hathaway (Berkshire Hathaway) CEO, for many years because of […]
After disappointing quarterly results for key indicators, Alibaba shares closed down 11% on Thursday.
Affected by this, the PHLX semiconductor industry index has risen sharply in the past month, and the stock of Micron Technology (Nasdaq: MU) has also regained a new life after experiencing a heavy setback for most of the year. The pessimistic predictions on the health of the memory industry put pressure on Micron’s stock in 2021, but the recent rebound suggests that the chip maker may once again gain investor confidence. Let's take a look at the reasons why the latest surge in Micron Technology's stock may continue.
(Bloomberg)-US President Joe Biden (Joe Biden) decided to nominate Lael Brainard (Lael Brainard) to replace Jerome Powell (Jerome Powell) as the chairman of the Federal Reserve. Traders provide a narrow window of opportunity-even if the impact fades relatively quickly. Most of the articles from Bloomberg, Startup Fever, are sweeping the world's last untapped video game city. The designer's understanding of the real city Elizabeth· Holmes faces his last chance to testify at trial Chronically Und
Four years ago, a failed medical device manufacturer called Bioptix changed its name to Riot Blockchain (NASDAQ: RIOT) and became a Bitcoin (CRYPTO: BTC) mining company. Earlier this year, Riot exchanged its stake in Coinsquare with new shares of the financial technology company Mogo (NASDAQ: MOGO). It also acquired Whitstone, which owns one of the largest Bitcoin mining facilities in North America.
Ines Ferre of Yahoo Finance detailed the trend of some stocks in midday trading.
After Alibaba's second-quarter results fell short of expectations, the share prices of Chinese companies including Nio Inc-ADR (NYSE: NIO) fell. Alibaba reported quarterly earnings of US$1.74 per share, which was lower than analysts’ consensus estimate of US$1.93. Alibaba also reported quarterly sales of US$31.15 billion, 2.8% lower than analysts’ consensus estimate of US$32.05 billion. This is an increase of 36% over the sales of 22.84 billion US dollars in the same period last year. The Chinese company’s stock is
"The king of hedge funds" says the United States has gone the wrong way. But he likes these stocks.
In this article, we will discuss Cathie Wood's latest stock selection under $10. If you want to skip our detailed analysis of these stocks, please go directly to Cathie Wood's 5 latest stock selections under $10. The portfolio value of ARK Investment Management, a New York-based hedge fund led by pioneering investor Casey Wood […]
The senior Wall Street analyst believes that this may be the next big technology investment.
Investors had to deal with some headwinds in the stock market this week, as major market benchmarks are still close to historical highs. The Dow Jones Industrial Average (DJINDICES: ^ DJI) failed to rise on Thursday, but the S&P 500 Index (SNPINDEX: ^ GSPC) and the Nasdaq Composite Index (NASDAQINDEX: ^ IXIC) recorded solid gains, putting them at the highest closing Historical price level. After the market closed, the earnings results of several well-known stocks caught the attention of investors.
Jared Blikre of Yahoo Finance broke down Workday's latest earnings report.
As of 11:25 am Eastern Time on Thursday, Alibaba Group's (NYSE: BABA) share price plummeted 10.9% after the Chinese technology giant reported that its revenue and profit for the second quarter of fiscal year 2022 were not accomplish. Analysts had expected Alibaba's revenue to be US$1.93 in this quarter’s estimated sales per share of more than US$32 billion. In contrast, Alibaba reported a profit of only US$1.74 and sales of only US$31.15 billion.
If you like simple, high-yield businesses, then this industry is worth studying. These are the three most noteworthy names.